Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool January 25, 2010 Brian Orelli	Pay-for-Delay Is Under the Spotlight It helps each side, but governments aren't thrilled with the idea.
The Motley Fool June 25, 2009 Brian Orelli	Loss of a Settlement Option Earlier this month the Federal Trade Commission came out with a report arguing for limited patent protection for drugs made by biotech companies. Now it's ratcheting up its complaints about pharmaceutical and generic-drug companies as well.
BusinessWeek June 24, 2010 Bliss & Decker	Ending the Silence of Generic Drugmakers The FTC says drugmakers are paying generic rivals not to compete.
The Motley Fool September 9, 2010 Jim Mueller	Today's Buy Opportunity: Teva Pharmaceutical Take advantage of this growing generic-drug maker.
Chemistry World January 20, 2010 Phil Taylor	Screw tightens on pay-for-delay drug deals Scrutiny of the tactics used by pharmaceutical companies to delay the entry of generics onto the market is rising on both sides of the Atlantic amid claims that the practice is costing consumers billions every year.
The Motley Fool September 22, 2009 Robert Steyer	Will Teva Be Forced to Take Its Own Medicine? Teva's biggest source of revenue and profit, the multiple sclerosis drug Copaxone, is facing a patent challenge.
The Motley Fool February 28, 2008 Brian Lawler	Benefiting From 2008's Generic Drugs While drug companies scramble to make up for lost revenue as their products are hit with patent expirations, other companies will benefit from the patent losses. Take a look at some winners and losers of drugs going off patent this year.
The Motley Fool September 30, 2011 Brian Orelli	When You Need More Than Just a Low-Margin Business Teva Pharmaceuticals, arguably the largest generic-drug maker, can use economies of scale more easily than smaller companies like Watson Pharmaceuticals or Par Pharmaceutical, but it's still pushing further into branded drugs.
The Motley Fool February 15, 2011 Brian Orelli	Obama Hates Your Drugmaker The president's proposal in favor of earlier generics would mean lower profits for some companies.
The Motley Fool June 22, 2006 Stephen D. Simpson	Merck Goes on the Attack Predator becomes prey in this latest twist in the generics game. Given how much the markets hate uncertainty, that could mean that big generic drug companies might go on sale for patient long-term investors.
The Motley Fool November 19, 2009 Brian Orelli	Pfizer's Generic Growth, With a Side of Sashimi A move into Japan isn't a bad idea, but it isn't going to save the company either.
The Motley Fool March 30, 2009 Brian Orelli	Here's Some Cash. Go Away. Bristol-Myers Squibb has to pay $2.1 million to settle a Federal Trade Commission investigation.
The Motley Fool July 14, 2008 Brian Orelli	Teva Gets a Taste of Its Own Medicine Momenta Pharmaceuticals and Novartis are challenging the patents on Teva Pharmaceutical's blockbuster multiple sclerosis drug Copaxone.
The Motley Fool December 3, 2008 Brian Orelli	High-Margin Generic Drugmakers -- An Oxymoron? The big profits come when a generic-drug maker doesn't have any competition.
The Motley Fool November 27, 2006 Brian Lawler	Teva and Pfizer Make Up The companies decide to play nice over generic versions of two of Pfizer's drugs.
Knowledge@Wharton	Drug Companies and the Patent Game: Fair Play or Foul? Is legal maneuvering a legitimate attempt by the big pharmaceutical companies to recover the huge costs of developing new drugs? Or are the brand-name firms inappropriately gaming the system for their own benefit, to the detriment of consumers and insurance companies?
The Motley Fool February 8, 2011 Brian Orelli	A Few Extra Years of Sales? Yes, Please! An EU-Canadian proposal could help drugmakers.
The Motley Fool March 13, 2008 Stephen Albainy-Jenei	Pfizer's Celebrex Aches and Pains The Court of Appeals for the Federal Circuit upholds a lower court's ruling that found Teva Pharmaceutical had infringed two of Pfizer's patents for Celebrex.
The Motley Fool December 30, 2008 Brian Orelli	2009's Generic Drugs: Who's at Risk The patent cliff is coming early for some drugmakers.
The Motley Fool January 31, 2008 Brian Orelli	Wyeth Calls Teva's Bluff Wyeth launches a generic version of its own heartburn drug.
The Motley Fool October 8, 2007 Brian Orelli	New FDA Regulations for Drugmakers To deal with a growing backlog of pending applications, the FDA plans to stop its first-come, first-served system.
The Motley Fool October 13, 2009 Dave Mock	A Big Upgrade for Teva Pharmaceutical This bullish call comes from more than just one analyst.
Chemistry World July 10, 2009 Sarah Houlton	Branded drugs' competition-free days numbered Authorities in the US and Europe are to look carefully at the tactics pharmaceutical firms use to delay competition from generic versions of their branded drugs.
The Motley Fool January 31, 2007 Brian Lawler	Mylan on the Generic Attack Two new drug approvals for the generic drugmaker come in the midst of a changing regulatory environment. Investors, take note.
The Motley Fool December 12, 2005 Rich Duprey	Patent? What Patent? Japanese drug firm Eisai sues Teva over a patented Alzheimer's treatment. Investors, take note.
The Motley Fool August 29, 2008 Brian Orelli	A Lawsuit Loss to Remember Barr Pharmaceuticals and Mylan get the patent overturned on Johnson & Johnson's Alzheimer's drug.
The Motley Fool October 18, 2010 Brian Orelli	Pfizer Flexes Its Generic Muscles The pharma giant moves farther into generic drugs.
The Motley Fool March 3, 2010 Brian Orelli	Judge's Ruling Has Brand and Generic Drugmakers Smiling A ruling on the patents on Merck's blood pressure medications Cozaar and Hyzaar benefited both Merck and the plaintiff in the suit, generic-drug maker Teva Pharmaceuticals. The defendant in the suit wasn't actually Merck but the Food and Drug Administration.
Managed Care September 2006	Payers, Consumers Benefit as Patents Expire The generic drug market seems ready to explode, according to reports from IMS Health and the Generic Pharmaceuticals Association.
The Motley Fool June 19, 2008 Brian Lawler	Pfizer's Small Lipitor Win Pfizer and the most prolific challenger of its Lipitor patents, Indian generic-drug manufacturer Ranbaxy, settle the vast majority of their litigation.
The Motley Fool September 15, 2008 Brian Orelli	Teva and FDA's Never-Ending Court Battle The Food and Drug Administration has won the latest installment of its grudge match with Teva Pharmaceuticals over the 180-day exclusivity period for generic versions of Johnson & Johnson's Risperdal.
The Motley Fool March 29, 2011 Brian Orelli	Much More Than a Generic Lawsuit The Supreme Court will decide generic-drug makers fate.
The Motley Fool May 28, 2008 Brian Orelli	A Rough Quarter for Generic-Drug Makers Investors rocked the smaller companies the most.
The Motley Fool March 7, 2007 Rich Duprey	Eisai Courts Danger The start of a patent-infringement trial sets the stage for the Japanese pharmaceutical's loss of protection on a major drug.
The Motley Fool January 30, 2007 Brian Lawler	Pfizer Fights a Generic Threat Pfizer attempts to fend off a generic threat in Canada for its top drug. It's a trial worth paying attention to for its shareholders, as Canada does represent one of the larger pharmaceutical markets in the world.
The Motley Fool June 26, 2006 Stephen D. Simpson	Is Novartis the Future of Generics? Merck's recent pricing action might just be the beginning of the end of generics as we know them. Investors, take note.
The Motley Fool March 15, 2005 Stephen D. Simpson	IVAX Is No Placebo The maker of generic drugs moves higher on fourth-quarter results that surprised Wall Street.
The Motley Fool May 15, 2008 Brian Orelli	Wanted: FDA Approval -- Pronto Teva and Amphastar have the courts on their side, but the FDA still stands in the way of a generic-drug launch.
The Motley Fool January 19, 2010 Brian Orelli	Pfizer Gets Serious About Generics Serious, as in a potential $4-billion-purchase serious.
The Motley Fool May 21, 2009 Brian Orelli	If You Can't Beat 'Em, Join 'Em: Pharma Goes Generic In the battle against generic rivals, it seems pharmaceutical companies would rather switch than fight. A pair of deals heralds Big Pharma's latest moves into the generic-drug world. See what Novartis and sanofi-aventis recently did.
The Motley Fool August 6, 2011 Sean Williams	10 Large Caps to Rule Them All There's nothing generic about this company. For the inaugural large-cap pick, I think we should revisit pharma's most impervious pipeline, Teva Pharmaceuticals.
Chemistry World April 25, 2014 Phillip Broadwith	Generics triumph in anti-inflammatory patent battle Pfizer has settled a long-running patent dispute with generics heavyweights Teva and Actavis, which will allow them to produce generic versions of Pfizers non-steroidal anti-inflammatory drug Celebrex (celecoxib) in the US.
The Motley Fool April 25, 2011 Sean Williams	Pharma's Most Impervious Pipeline An investment in generics doesn't have to be a bad thing.
The Motley Fool March 23, 2010 Brian Orelli	No Patent! No Generics? Take Advantage of the Situation Enjoy it while it lasts, pharma.
The Motley Fool April 5, 2011 Brian Orelli	Suit Settlement Sends Shares Skyrocketing Cubist Pharmaceuticals gets concessions as it settles its patent suit with Teva.
The Motley Fool October 16, 2006 Brian Lawler	The Coming Generic Drug Boom Generic drugmakers are poised to profit from several key factors. Investors, take note.
The Motley Fool November 3, 2010 Brian Orelli	Teva's New Drugs Pay Off The generic-drug maker keeps generating big profits.
The Motley Fool March 5, 2008 Brian Orelli	Teva Wants the FDA to Do What? Teva wants the FDA to reinstate another drugmaker's patent.
The Motley Fool March 19, 2009 Brian Orelli	Teva: An Equal-Opportunity Bully Making money by picking on the little guy, too.
The Motley Fool January 3, 2008 Brian Orelli	8 Generic-Drug Makers for 2008 Generic-drug makers can predict the growth of their industry, because it's written right in the patent-expirations column of the FDA's orange book. Here's a brief look at eight generic-drug makers worth closer scrutiny.